LEO Pharma

LEO Pharma closes acquisition of Bayer’s prescription dermatology business in the United States

Del

LEO Pharma and Bayer announced today the completion of the relevant closing conditions to allow the transfer of Bayer’s prescription dermatology business to LEO Pharma in the United States.

Ballerup, Denmark / Leverkusen, Germany, September 4th, 2018 – LEO Pharma and Bayer announced today the completion of the relevant closing conditions to allow the transfer of Bayer’s prescription dermatology business to LEO Pharma in the United States. Closing in all other countries is expected during the second half of 2019, subject to the fulfillment of customary closing conditions.

LEO Pharma and Bayer entered into an agreement for the acquisition of Bayer’s global portfolio of prescription dermatology products as announced on July 31, 2018. This includes Finacea® (azelaic acid) Foam for the topical treatment of mild to moderate rosacea, a range of topical steroids and other products for the treatment of acne and fungal skin infections.

Chris Posner, President and CEO of LEO Pharma US, said: “This is an exciting time for LEO Pharma in the US. Completing this acquisition enables LEO Pharma US to significantly broaden its therapeutic areas and skilled workforce, ultimately providing more treatment options for dermatology patients across the country.”

“Our Rx Dermatology colleagues have worked diligently to develop this business over many years,” said Patrick Lockwood-Taylor, President of Bayer’s Consumer Health business in North America. “With the closing of the transaction in the US, the business is now in the best hands for future growth and allows Bayer to focus on our core OTC business. I want to thank the Bayer and LEO teams for their great collaboration that brought us to this milestone in such a short period of time.”

As announced as part of the agreement, LEO Pharma will acquire the global product rights, except for Afghanistan and Pakistan, and take over the sales and marketing organizations in 14 countries, as well as a factory in Segrate, Italy. Assuming the successful close, around 450 people will join LEO Pharma as part of this transaction.

Subject to applicable laws, LEO Pharma and Bayer will continue to work closely together with the aim of securing an effective transition of the business in the rest of the world and an uninterrupted supply of prescription dermatology treatments that patients have come to rely on and trust.

- END -

 

 

About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 130 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company headquartered in Denmark has devoted decades of research and development to delivering products and solutions to people with skin conditions. In 2017 LEO Pharma employed around 5,200 people worldwide and had sales of 1.4 billion euros. For more information, go to:

www.leo-pharma.com

www.linkedin.com/company/leo-pharma

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of 35.0 billion euros. Capital expenditures amounted to 2.4 billion euros, R&D expenses to 4.5 billion euros. For more information, go to www.bayer.com.

Global Media Contacts
LEO Pharma A/S
Henrik Kyndlev
henrik.kyndlev@leo-pharma.com
Tel. +45 3140 6180

Bayer
Tricia McKernan
tricia.mckernan@bayer.com

Tel. +41 58 272 7871

Christian Hartel

christian.hartel@bayer.com
Tel. +49 214 30 47686


 

 

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Kontakter

Global Media Contacts

LEO Pharma A/S
Henrik Kyndlev
henrik.kyndlev@leo-pharma.com
Tel. +45 3140 6180

Bayer
Tricia McKernan
tricia.mckernan@bayer.com
Tel. +41 58 272 7871

Christian Hartel
christian.hartel@bayer.com
Tel. +49 214 30 47686

Information om LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 130 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company headquartered in Denmark has devoted decades of research and development to delivering products and solutions to people with skin conditions. In 2017 LEO Pharma employed around 5,200 people worldwide and had sales of 1.4 billion euros. For more information, go to:

www.leo-pharma.com

www.linkedin.com/company/leo-pharma

 

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of 35.0 billion euros. Capital expenditures amounted to 2.4 billion euros, R&D expenses to 4.5 billion euros. For more information, go to www.bayer.com.

Følg pressemeddelelser fra LEO Pharma

Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.

Flere pressemeddelelser fra LEO Pharma

LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics17.9.2018 22:34pressemeddelelse

LEO Pharma A/S, a global leader in medical dermatology, and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies’ pipelines. This alliance expands the existing partnership of the two companies signed in November 2016 to jointly discover and develop antibody-based therapies in dermatology.

LEO Pharma A/S indlicenserer lovende ny lægemiddelkandidat fra JW Pharmaceutical til oral behandling af atopiske dermatitis24.8.2018 10:23pressemeddelelse

LEO Pharma får eksklusivrettigheder til at udvikle og kommercialisere JW1601 på det globale marked ekskl. Korea. JW1601 er en ny lægemiddelkandidat beregnet til oral behandling af atopisk dermatitis. JW Pharmaceutical modtager op til 402 mio. USD på forhånd og i milepælsbetalinger. Udover milepælsbetalinger vil der blive tildelt royalty.

LEO Pharma A/S og FibroTx LLC indgår samarbejde om udvikling af ikke-invasiv hudsampling13.6.2018 09:45pressemeddelelse

Ballerup, den 13. juni, 2018 – LEO Pharma og FibroTx har indgået samarbejde om udviklingen af ny teknologi til ikke-invasiv hudsampling. FibroTx er et biotek-selskab med base i Estland, som udvikler innovative værktøjer til målrettet dermatologisk behandling. Samarbejdet er det første skridt på vejen mod at kunne måle biomarkører fra hudoverfladen hos patienter med atopisk dermatitis ved brug af en ikke-invasiv hudsampling-metode, som FibroTx har udviklet. Metoden kan anvendes til at bestemme omfang af sygdommen samt til at overvåge effekten af behandling. Det er endvidere også muligt, at metoden vil kunne anvendes til at vurdere fremtidig effekt af behandling. Samarbejdet mellem LEO Pharma og FibroTx om udviklingen af målrettede medicinske værktøjer, der medfører mindst muligt ubehag for patienterne, styrker begge virksomheders indsats for at forbedre livet for mennesker, som er ramt af atopisk dermatitis. ”Vi er glade for at indgå samarbejde med FibroTx om deres nye teknologi, som vi

LEO Pharma ansætter Christian Antoni som Senior Vice President for Global Development, R&D28.5.2018 13:07pressemeddelelse

Ballerup, den 28. maj, 2018 – Christian Antoni, cand. med. og ph.d tiltræder som Senior Vice President for Global Development, R&D hos LEO Pharma 1. juni 2018 med globalt ansvar for Chemistry Manufacturing & Control, Regulatory Affairs, Clinical Operations, Medical Science & Safety samt projektledelse. Han vil referere til Kim Kjøller, Executive Vice President for Global Research & Development.

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.

Besøg vores nyhedsrum